Agilent Closes $600M 4.9% Senior Notes Due 2032

Agilent closed a $600 million issuance of 4.90% senior notes due 2032 on June 25, 2026. The new notes increase the company's outstanding senior debt base, which the filings show at approximately $3.3 billion (including the 2034 notes bearing 4.75%). On a revenue scale, Agilent reported $6,948 million in net revenue for fiscal 2025, so the $600 million principal is equivalent to roughly 8.6% of FY2025 net revenue. Agilent recorded $112 million of interest expense in FY2025, a 17% year-over-year increase, highlighting sensitivity of reported interest costs to its debt load and interest rates. Fiscal metrics relevant to investors include FY2025 R&D of $455M, capex of $450M, dividends of $0.992 per share, and recent capital allocation actions (a $2B 2023 repurchase program completed in September 2025 and a 2024 repurchase program described as ongoing in filings).

The notes add fixed-rate senior debt maturing in 2032 at a 4.90% coupon, which locks in borrowing costs for that tranche and affects the company’s interest-payments profile over the medium term. Given Agilent's stated exposure to rising rates and the rise in interest expense in FY2025, investors should view the issuance in the context of overall leverage and cash-flow allocation: the company continues to fund operations and strategic initiatives (including BIOVECTRA CDMO expansion and product/service investments) while maintaining dividends and share-repurchase activity noted in filings. Operationally, Agilent's FY2025 results showed 7% revenue growth to $6,948M with segment contributions across Life Sciences & Diagnostics (39% of revenue), Agilent CrossLab (42%), and Applied Markets (19%). These revenue and segment dynamics are relevant when assessing the company's ability to service additional debt from recurring services/consumables and product sales.

Filings indicate Agilent's debt profile already included multi-billion dollars of senior notes and that rising rates have increased interest expense. The new 4.90% notes are a fixed-rate obligation; their impact on annual cash interest will depend on the company's overall mix of fixed- and floating-rate liabilities and future refinancing activity. Investors should consider that interest expense rose to $112M in FY2025 (+17% YoY) and that Agilent highlighted debt vulnerability to rising rates in its risk disclosures.

Agilent's filings describe continued capital deployment across several priorities: CDMO expansion (BIOVECTRA), R&D (FY2025: $455M), and capex (FY2025: $450M). Filings also note completed and ongoing share repurchase programs and a continued dividend. The $600M note issuance sits alongside these commitments; the filings do not specify proceeds usage for this particular issuance, so investors should rely on subsequent corporate disclosures for intended allocation.